Botox Isn’t The Only Wrinkle-Fighter Available Today: Learn About Xeomin

A new cosmetic anti-wrinkle injection is proving to be a viable competitor against Botox. Xeomin is an effective tool to improve the look of mild, moderate and severe frown lines. Fine facial lines and wrinkles are the first signs of aging. Botox has been the gold standard for over a decade, but a new cosmetic wrinkle treatment is showing great promise as a fast acting injected medication with ingredients that have been attracting younger patient.

Xeomin has been recently released, making it the newest treatment available for erasing wrinkles and smoothing skin much like its predecessor, Botox. Xeomin and Botox share the identical active ingredient, botulinum toxin A. Botulinum toxin is a naturally occurring purified neurotoxin used to treat muscle spasms, abnormal neck pain, and its most popular use, wrinkles. This neurotoxin enables both Cosmetic anti-wrinkle injections have recently attracted younger users as a preventative solution. Before wrinkles even form, patients stop the unnecessary muscle contractions, which delay the fine lines and wrinkles later in life.

Xeomin cuts that line of communication between the brain and the facial nerves, which ultimately prevents the signal from reaching the muscle. When the muscle isn’t signaled to contract, it remains in a relaxed state and stops wrinkles from continuing. These movements are only micro-movements that form undesirable lines along the face overtime, so it does not prevent you from making facial expressions altogether.

Botox and Xeomin have the ability to treat glabellar wrinkles, crow’s feet, and fine lines around the eyes, upper lip and forehead. Similar to Botox, the results tend to last three to four months and fade away gradually. Xeomin has thrived on the global market since 2005 and with its recent introduction to the U.S. market, this new wrinkle reducer will provide patients with an impressive and formidable cosmetic medication.

Dr. Cameron K. Rokhsar, M.D., was given early access to Xeomin two years prior to its release, providing him with an unrivaled expertise on the product’s uses. He was selected along with a specialized group of physicians to have early access to Dysport and Xeomin in order to test their efficacy, providing Dr. Rokhsar with an exclusive expertise and knowledgeable precision.

Leave a Reply

Your email address will not be published. Required fields are marked *